The Immune Regulator NLRX1 Limits Inflammatory Neurodegeneration in the Anterior Visual Pathway

common TEAE (71.1% vs 71.6%, respectively).In the prior-rituximabtreated group, no deaths occurred; no patients experienced TEAEs/ TESAEs leading to C5IT withdrawal.There were no differences in TEAE/TESAE incidence rates when analyzed by time since last rituximab use. ConclusionsNo differences in safety were observed among prior-rituximab-treated patients in the PREVENT and CHAMPION-NMOSD studies.These findings provide important information to guide clinical decisionmaking when considering a switch from rituximab to C5IT in patients with AQP4-Ab+ NMOSD who received rituximab within the preceding 3-12 months.Study Supported By: Alexion, AstraZeneca Rare Disease.Disclosure: Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma.Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a